Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma [J Immunothera Cancer, 4, (2016), (28)] DOI:10.1186/s40425-016-0132-2

Mira A. Patel; Jennifer E. Kim; Debebe Theodros; Ada Tam; Esteban Velarde; Christina M. Kochel; Brian Francica; Thomas R. Nirschl; Ali Ghasemzadeh; Dimitrios Mathios; Sarah Harris-Bookman; Christopher C. Jackson; Christina Jackson; Xiaobu Ye; Phuoc T. Tran; Betty Tyler; Vladimir Coric; Mark Selby; Henry Brem; Charles G. Drake; Drew M. Pardoll; Michael Lim

ArticleOPEN ACCESS

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma [J Immunothera Cancer, 4, (2016), (28)] DOI:10.1186/s40425-016-0132-2

Journal for ImmunoTherapy of Cancer

DOI: 10.1186/s40425-016-0181-6

0Citations

9Readers

Abstract

Unfortunately, after publication of this article [1], it was noticed that a funding source was not mentioned. Bristol-Myers Squibb was intended to be included in the 'Financial Support' section of the article.

Cite

CITATION STYLE

APA

Patel, M. A., Kim, J. E., Theodros, D., Tam, A., Velarde, E., Kochel, C. M., … Lim, M. (2016, November 4). Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma [J Immunothera Cancer, 4, (2016), (28)] DOI:10.1186/s40425-016-0132-2. Journal for ImmunoTherapy of Cancer. BioMed Central Ltd. https://doi.org/10.1186/s40425-016-0181-6

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma [J Immunothera Cancer, 4, (2016), (28)] DOI:10.1186/s40425-016-0132-2

Abstract

Cite

Register to see more suggestions